Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 32117-32118 [2012-13154]
Download as PDF
<![CDATA[
srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 105 / Thursday, May 31, 2012 / Notices
School: Based on evidence and findings
of an inquiry conducted jointly by
Brigham and Women’s Hospital (BWH)
and Harvard Medical School (HMS) and
additional evidence gathered by the
Office of Research Integrity (ORI) during
its oversight review, ORI found that Dr.
Juan Ma, former Research Fellow, BWU,
engaged in research misconduct in
research supported by National Cancer
Institute (NCI), National Institutes of
Health (NIH), grant 5 P01 CA120964.
ORI found that the Respondent
knowingly and intentionally fabricated
and falsified data in portions of figures
in an unpublished manuscript titled
‘‘TSC1 loss synergizes with KRAS
activation in lung cancer development
and confers rapamycin sensitivity’’ by
M.-C. Liang, J. Ma, L. Chen, P.
Kozlowski, W. Qin, D. Li, T.
Shimamura, M.L. Sos, R. Thomas, D.
Neil Hayes, M. Meyerson, D.J.
Kwiatkowski, and K.-K. Wong,
submitted to the Journal of Clinical
Investigation (JCI) on August 5, 2008,
and in revised form on October 21, 2008
(hereafter referred to as the ‘‘JCI
manuscript’’). Specifically, Respondent
committed research misconduct by
knowingly and intentionally:
• Falsifying and/or fabricating those
portions of the immunoblots in JCI
manuscript Figure 1C, to show that in
TsclL/L and TscL/∂ mouse lung cancer
cells compared with KRAS induced
lung cancer cells, there were reduced
Tsc1 and Tsc2 protein levels, reduced
phospho-AKT–S473 levels, and
increased phospho-S6–S249/244 levels,
consistent with the hypothesis that
introduction of the Tsc1L gene resulted
in mTORC1 activation.
• Falsifying and/or fabricating those
portions of the immunoblots in Figure
3A of the JCI manuscript to show data
consistent with the hypothesized TNS
null signaling lung tumor cells:
Functional loss of Tsc1/Tsc2, high
phospho-S6–S249/244 levels, and low
phospho-AKT–S473, with recovery of
phospho-AKT–S473 after Rapamycin
treatment.
• Falsifying and/or fabricating those
portions of the immunoblots in Figure
3B of the JCI manuscript by (i) adding
a band in the Tsc2 lane for control cells
for the IP blot, and (ii) weakening the
Tsc2 band for one of the tumor lysates.
• Falsifying and/or fabricating
immunoblots in Figures 5A and 5B of
the JCI manuscript so that the data
appeared to indicate that TSC
reconstitution in TSC null (TNS) cell
lines led to reduction of pS6–S240/244
levels during serum deprivation (in the
absence of growth factors), as well as
increased pAKT(S473) levels in
response to serum stimulation.
VerDate Mar<15>2010
17:53 May 30, 2012
Jkt 226001
• The JCI manuscript was accepted by
JCI on December 8, 2008, but it was
withdrawn by one of the authors on
January 6, 2009.
ORI found that Respondent’s knowing
and intentional falsification and
fabrication of data constitutes research
misconduct within the meaning of 42
CFR 93.103.
The following administrative actions
have been implemented for a period of
three (3) years, beginning on May 12,
2012:
(1) Any institution that submits an
application for U.S. Public Health
Service (PHS) support for a research
project on which Respondent’s
participation is proposed or that uses
him in any capacity on PHS-supported
research must concurrently submit a
plan for supervision of his duties to the
funding agency for approval; the
supervisory plan must be designed to
ensure the scientific integrity of his
research contribution; Respondent must
ensure that a copy of the supervisory
plan is also submitted to ORI by the
institution; Respondent will not
participate in any PHS-supported
research until such a supervisory plan is
submitted to ORI;
(2) Respondent will ensure that any
institution employing him submits, in
conjunction with application for PHS
funds or any report, manuscript, or
abstract of PHS-funded research in
which he is involved, a certification that
the data provided by him are accurately
reported in the application or report;
Respondent must ensure that the
institution send the certification to ORI;
this certification shall be submitted no
later than one month before funding and
concurrently with any report,
manuscript, or abstract; and
(3) Respondent is prohibited from
serving in any advisory capacity to PHS,
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Director, Division of Investigative Oversight,
Office of Research Integrity.
[FR Doc. 2012–13126 Filed 5–30–12; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
32117
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH or Advisory
Board), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the
aforementioned committee:
Board Public Meeting Times and
Dates (All times are Mountain Time):
8:15 a.m.–5:15 p.m., June 19, 2012.
8:15 a.m.–5:45 p.m., June 20, 2012.
8:15 a.m.–12 p.m., June 21, 2012.
Public Comment Times and Dates (All
times are Mountain Time):
5:15 p.m.–6:15 p.m.*, June 19, 2012.
6 p.m.–7 p.m.*, June 20, 2012.
* Please note that the public comment
periods may end before the times
indicated, following the last call for
comments. Members of the public who
wish to provide public comments
should plan to attend public comment
sessions at the start times listed.
Place: Courtyard Santa Fe, 3347
Cerrillos Road, Santa Fe, New Mexico
87507, Telephone: (800) 777–3347, Fax:
(505) 473–5128. Audio Conference Call
via FTS Conferencing, the USA toll-free,
dial-in number is 1–866–659–0537 with
a pass code of 9933701.
Status: Open to the public, limited
only by the space available. The meeting
space accommodates approximately 150
people.
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule, advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule, advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program, and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
E:\FR\FM\31MYN1.SGM
31MYN1
srobinson on DSK4SPTVN1PROD with NOTICES
32118
Federal Register / Vol. 77, No. 105 / Thursday, May 31, 2012 / Notices
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to the CDC.
NIOSH implements this responsibility
for CDC. The charter was issued on
August 3, 2001, renewed at appropriate
intervals, and will expire on August 3,
2013.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters To Be Discussed: The agenda
for the Advisory Board meeting
includes: NIOSH Program Update;
Department of Labor Program Update;
Department of Energy Program Update;
NIOSH 10-Year Program Review
Implementation; SEC petitions for:
Winchester Engineering and Analytical
Center (Winchester, MA), Weldon
Spring Plant (Weldon Spring, MO),
Hanford (1972–1983), Los Alamos
National Laboratory, General Steel
Industries (Granite City, IL), Clarksville
Facility (Clarksville, TN), Mound Plant,
Titanium Alloys Manufacturing
(Niagara Falls, NY), and Medina Facility
(San Antonio, TX); Non-qualifying SEC
Petitions and SEC Petitions Status
Update; Linde Ceramics Work Group
Site Profile Review; and Board Work
Sessions.
The agenda is subject to change as
priorities dictate.
In the event an individual cannot
attend, written comments may be
submitted in accordance with the
redaction policy provided below. Any
written comments received will be
provided at the meeting and should be
submitted to the contact person below
well in advance of the meeting.
Policy on Redaction of Board Meeting
Transcripts (Public Comment): (1) If a
person making a comment gives his or
her name, no attempt will be made to
redact that name. (2) NIOSH will take
reasonable steps to ensure that
individuals making public comment are
aware of the fact that their comments
(including their name, if provided) will
appear in a transcript of the meeting
VerDate Mar<15>2010
17:53 May 30, 2012
Jkt 226001
posted on a public Web site. Such
reasonable steps include: (a) A
statement read at the start of each public
comment period stating that transcripts
will be posted and names of speakers
will not be redacted; (b) A printed copy
of the statement mentioned in (a) above
will be displayed on the table where
individuals sign up to make public
comments; (c) A statement such as
outlined in (a) above will also appear
with the agenda for a Board Meeting
when it is posted on the NIOSH Web
site; (d) A statement such as in (a) above
will appear in the Federal Register
Notice that announces Board and
Subcommittee meetings. (3) If an
individual in making a statement
reveals personal information (e.g.,
medical information) about themselves
that information will not usually be
redacted. The NIOSH FOIA coordinator
will, however, review such revelations
in accordance with the Freedom of
Information Act and the Federal
Advisory Committee Act and if deemed
appropriate, will redact such
information. (4) All disclosures of
information concerning third parties
will be redacted. (5) If it comes to the
attention of the DFO that an individual
wishes to share information with the
Board but objects to doing so in a public
forum, the DFO will work with that
individual, in accordance with the
Federal Advisory Committee Act, to
find a way that the Board can hear such
comments.
CONTACT PERSON FOR MORE INFORMATION:
Theodore Katz, Executive Secretary,
NIOSH, CDC, 1600 Clifton Road, M/S E–
20, Atlanta, Georgia 30333, telephone:
(513) 533–6800, toll free: 1 (800) CDC–
INFO, email: dcas@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: May 23, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–13154 Filed 5–30–12; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10436 and CMS–
855B]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, HHS.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
1. Type of Information Collection
Request: New collection; Title of
Information Collection: Evaluation of
the Multi-Payer Advanced Primary Care
Practice Demonstration; Use: On
September 16, 2009, the Department of
Health and Human Services announced
the establishment of the Multi-Payer
Advanced Primary Care Practice
(MAPCP) Demonstration, under which
Medicare joined Medicaid and private
insurers as a payer participant in statesponsored initiatives to promote the
principles that characterize advanced
primary care, often referred to as the
‘‘patient-centered medical home’’
(PCMH). CMS selected eight states to
participate in this demonstration:
Maine, Vermont, Rhode Island, New
York, Pennsylvania, North Carolina,
Michigan, and Minnesota. These states
vary on a number of important
dimensions, such as features of their
public (Medicaid) and private insurance
markets, delivery system, prior
experience with medical home
initiatives, and nature of their statesponsored multi-payer initiative.
CMS is conducting an evaluation of
the demonstration to assess the effects
of advanced primary care practice when
supported by Medicare, Medicaid, and
AGENCY:
E:\FR\FM\31MYN1.SGM
31MYN1
]]>Agencies
[Federal Register Volume 77, Number 105 (Thursday, May 31, 2012)]
[Notices]
[Pages 32117-32118]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-13154]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Board on Radiation and Worker Health (ABRWH or Advisory
Board), National Institute for Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42
CFR 83.15(a), the Centers for Disease Control and Prevention (CDC),
announces the following meeting of the aforementioned committee:
Board Public Meeting Times and Dates (All times are Mountain Time):
8:15 a.m.-5:15 p.m., June 19, 2012.
8:15 a.m.-5:45 p.m., June 20, 2012.
8:15 a.m.-12 p.m., June 21, 2012.
Public Comment Times and Dates (All times are Mountain Time):
5:15 p.m.-6:15 p.m.*, June 19, 2012.
6 p.m.-7 p.m.*, June 20, 2012.
* Please note that the public comment periods may end before the
times indicated, following the last call for comments. Members of the
public who wish to provide public comments should plan to attend public
comment sessions at the start times listed.
Place: Courtyard Santa Fe, 3347 Cerrillos Road, Santa Fe, New
Mexico 87507, Telephone: (800) 777-3347, Fax: (505) 473-5128. Audio
Conference Call via FTS Conferencing, the USA toll-free, dial-in number
is 1-866-659-0537 with a pass code of 9933701.
Status: Open to the public, limited only by the space available.
The meeting space accommodates approximately 150 people.
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key functions of the Advisory Board include providing advice
on the development of probability of causation guidelines which have
been promulgated by the Department of Health and Human Services (HHS)
as a final rule, advice on methods of dose reconstruction which have
also been promulgated by HHS as a final rule, advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program, and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC).
[[Page 32118]]
In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to the CDC. NIOSH implements this
responsibility for CDC. The charter was issued on August 3, 2001,
renewed at appropriate intervals, and will expire on August 3, 2013.
Purpose: This Advisory Board is charged with (a) providing advice
to the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advise the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class.
Matters To Be Discussed: The agenda for the Advisory Board meeting
includes: NIOSH Program Update; Department of Labor Program Update;
Department of Energy Program Update; NIOSH 10-Year Program Review
Implementation; SEC petitions for: Winchester Engineering and
Analytical Center (Winchester, MA), Weldon Spring Plant (Weldon Spring,
MO), Hanford (1972-1983), Los Alamos National Laboratory, General Steel
Industries (Granite City, IL), Clarksville Facility (Clarksville, TN),
Mound Plant, Titanium Alloys Manufacturing (Niagara Falls, NY), and
Medina Facility (San Antonio, TX); Non-qualifying SEC Petitions and SEC
Petitions Status Update; Linde Ceramics Work Group Site Profile Review;
and Board Work Sessions.
The agenda is subject to change as priorities dictate.
In the event an individual cannot attend, written comments may be
submitted in accordance with the redaction policy provided below. Any
written comments received will be provided at the meeting and should be
submitted to the contact person below well in advance of the meeting.
Policy on Redaction of Board Meeting Transcripts (Public Comment):
(1) If a person making a comment gives his or her name, no attempt will
be made to redact that name. (2) NIOSH will take reasonable steps to
ensure that individuals making public comment are aware of the fact
that their comments (including their name, if provided) will appear in
a transcript of the meeting posted on a public Web site. Such
reasonable steps include: (a) A statement read at the start of each
public comment period stating that transcripts will be posted and names
of speakers will not be redacted; (b) A printed copy of the statement
mentioned in (a) above will be displayed on the table where individuals
sign up to make public comments; (c) A statement such as outlined in
(a) above will also appear with the agenda for a Board Meeting when it
is posted on the NIOSH Web site; (d) A statement such as in (a) above
will appear in the Federal Register Notice that announces Board and
Subcommittee meetings. (3) If an individual in making a statement
reveals personal information (e.g., medical information) about
themselves that information will not usually be redacted. The NIOSH
FOIA coordinator will, however, review such revelations in accordance
with the Freedom of Information Act and the Federal Advisory Committee
Act and if deemed appropriate, will redact such information. (4) All
disclosures of information concerning third parties will be redacted.
(5) If it comes to the attention of the DFO that an individual wishes
to share information with the Board but objects to doing so in a public
forum, the DFO will work with that individual, in accordance with the
Federal Advisory Committee Act, to find a way that the Board can hear
such comments.
Contact Person for More Information: Theodore Katz, Executive
Secretary, NIOSH, CDC, 1600 Clifton Road, M/S E-20, Atlanta, Georgia
30333, telephone: (513) 533-6800, toll free: 1 (800) CDC-INFO, email:
dcas@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: May 23, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2012-13154 Filed 5-30-12; 8:45 am]
BILLING CODE 4163-18-P
